7 July 2015: Sharp Clinical Services, part of UDG Healthcare plc, (LON: UDG), the leading international provider of healthcare services, has expanded its storage and packaging facilities in the UK by an additional 5,000 square feet, creating an additional 10 roles at the site. The new facility based in Crickhowell is now the fourth unit of the existing Waller House building and comprises of 150 additional pallet spaces and two assembly lines. The Company’s investment is in response to new product introductions approved by the regulatory authorities.
Sharp Clinical Services is a leading provider of specialist clinical supply chain services to both large pharmaceutical and small biotech companies in the UK and US, from drug product development, analytical and manufacturing services through to increasingly complex clinical trial supplies packaging, clinical labeling and clinical distribution services. Sharp Clinical Services has a proven track record in managing the entire clinical supply chain and has a Global Depot Network of 18 depots supporting over 25 countries.
Ian Morgan, General Manager of Sharp Clinical Services UK, commented on the expansion: “The expansion of the Crickhowell facility is a landmark moment for Sharp Clinical Services in the UK, and enables us to deliver excellent, high quality service to our existing and new customers as demand for our services increases in the UK. The first commercial test ran at the end of May and full production will begin in July.”
Frank Lis, President of Sharp Clinical Services added: “This expansion has increased our global footprint and will allow us to provide our customers with a full range of services, from formulation development and pre-clinical supplies through to product launch.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
2 Commerce Drive
Cranbury, NJ 08512